Secretome-Mediated Antimicrobial and Immunomodulatory Activity of Lactobacillus johnsonii Against Multidrug-Resistant Enteroaggregative Escherichia coli

This study demonstrates that *Lactobacillus johnsonii* exerts potent, secretome-dependent antimicrobial and immunomodulatory effects against multidrug-resistant enteroaggregative *Escherichia coli* by inhibiting biofilm formation, displacing bacterial adhesion, and reducing inflammatory markers, thereby supporting its potential as a biotherapeutic candidate for antibiotic-resistant enteric infections.

The Gist

Imagine your gut is a bustling, crowded city. Usually, the residents (good bacteria) and the visitors (food) live in harmony. But sometimes, a dangerous gang of invaders called Enteroaggregative E. coli (EAEC) moves in. These aren't just any invaders; they are the "super-villains" of the bacterial world. They build fortified bunkers called biofilms (like a sticky fortress made of slime), they resist almost every antibiotic we throw at them (they are "Multidrug-Resistant"), and they cause persistent, nasty diarrhea, especially in children.

For years, doctors have tried to fight these villains with stronger and stronger antibiotics, but the villains keep evolving and winning. This paper introduces a new hero: a friendly bacterium named Lactobacillus johnsonii (let's call him "L. Johnny").

Here is the story of how L. Johnny fights back, explained simply:

1. The Hero's Training (Probiotic Superpowers)

Before L. Johnny can fight, he has to survive the journey to the gut. The researchers tested if he could handle the harsh environment of the human stomach and intestines.

• The Acid Test: The stomach is like a vat of acid. L. Johnny didn't just survive; he thrived in it.
• The Sticky Situation: To be a good bodyguard, you need to stick to the walls. L. Johnny is incredibly "sticky" (hydrophobic) and loves to clump together with his friends (autoaggregation). This means he can quickly grab a spot on the intestinal wall and set up a permanent base camp before the bad guys arrive.

2. The Battle Plan (How He Fights)

The researchers watched L. Johnny fight the super-villain EAEC in a lab dish. He didn't use a sword; he used a secret weapon (a "secretome").

• The Invisible Shield: When L. Johnny was placed near the bad bacteria, he released a cloud of invisible, toxic chemicals. It was like L. Johnny was spraying a fog that made the bad bacteria sick and die. Interestingly, this fog was even more effective than the antibiotic Gentamicin, which the bad bacteria were supposed to be immune to!
• Breaking the Fortresses: The bad bacteria build slime fortresses (biofilms) to hide. L. Johnny didn't just knock on the door; he dissolved the fortress. When the researchers added L. Johnny, the bad bacteria's slime castle crumbled, and over 80% of the invaders inside were wiped out.
• The "Turf War" (Exclusion): Imagine the gut wall is a crowded dance floor. L. Johnny is a great dancer who gets there early.
  • Exclusion: If L. Johnny gets on the dance floor first, he fills up all the spots. When the bad bacteria try to arrive, there's nowhere for them to stand, so they bounce off.
  • Displacement: Even if the bad bacteria get there first, L. Johnny is strong enough to push them off the dance floor and take their spot.
  • Note: If they arrive at the exact same time, it's a messy tie. L. Johnny works best if he gets a head start!

3. Calming the Chaos (Immunomodulation)

When the bad bacteria attack, the body's security guards (immune cells called macrophages) go into a frenzy, shouting so loud (releasing Nitric Oxide) that they start damaging the city itself (inflammation).

• L. Johnny acts like a peacekeeper. He didn't just kill the bad guys; he also told the security guards to "calm down." He reduced the inflammatory shouting by nearly 70%, preventing the city from burning itself down while fighting the invaders.

4. The Secret Sauce (What's in the Fog?)

The researchers wanted to know exactly what was in L. Johnny's secret weapon. They filtered out the bacteria and kept only the liquid they left behind (the "cell-free supernatant").

• They ran this liquid through a high-tech filter (FPLC) to separate it into different "fractions" (like sorting a bag of mixed candies by size and color).
• They found two specific "candies" (Fractions S5 and S6) that were the real heavy hitters. Even after 6 hours, these two fractions were still killing the bad bacteria.
• The Twist: It wasn't just about L. Johnny eating all the food (nutrient competition). The bad bacteria still had plenty to eat, but they were still dying. This proves L. Johnny is using a chemical weapon, not just a starvation tactic.

The Big Picture

This study is like finding a new, natural "super-antibiotic" that doesn't come from a lab but from a friendly yogurt bacterium.

• The Problem: Bad bacteria are becoming immune to our medicine.
• The Solution: A friendly bacteria (L. Johnny) that can survive the stomach, stick to the gut, dissolve the bad bacteria's fortresses, and calm the body's panic.
• The Future: While this is currently a lab experiment, it suggests that in the future, we might treat stubborn gut infections not with harsh drugs, but with a "peacekeeping force" of good bacteria that uses its own secret chemical weapons to restore order.

In short: L. Johnny is the ultimate bodyguard for your gut, capable of outsmarting, out-sticking, and out-killing the toughest bacterial villains without needing a pharmacy.

Technical Summary

1. Problem Statement

Enteroaggregative Escherichia coli (EAEC) is a leading cause of persistent diarrhea in children in low- and middle-income countries, often resulting in growth faltering and cognitive impairment. The clinical management of EAEC is increasingly compromised by the emergence of Multidrug-Resistant (MDR) strains. These strains exhibit resistance to first-line antibiotics (ampicillin, ciprofloxacin, azithromycin, amoxicillin, gentamicin) and possess a unique ability to form structured biofilms on the intestinal mucosa. Biofilm formation shields the bacteria from antimicrobial peptides and antibiotics, rendering standard treatments ineffective. There is an urgent need for non-antibiotic therapeutic strategies that can target both planktonic and biofilm-associated MDR EAEC.

2. Methodology

The study utilized a comprehensive in vitro approach to evaluate a specific isolate of Lactobacillus johnsonii (originally isolated from homemade Indian curd) against a clinically confirmed MDR EAEC isolate.

• Strain Characterization:
  • Probiotic Traits: Assessed gastrointestinal stress tolerance (acid, bile, phenol), surface hydrophobicity (MATH assay), and autoaggregation.
  • MDR Confirmation: The EAEC isolate was verified for resistance to six antibiotics via broth microdilution.
• Antimicrobial & Anti-Biofilm Assays:
  • Agar Overlay: Measured zones of inhibition (ZOI) compared to gentamicin.
  • Biofilm Inhibition: Co-cultured live and heat-killed L. johnsonii with EAEC; quantified biofilm biomass via crystal violet staining and viable counts (CFU).
• Host Interaction Models:
  • Adherence/Competition: Used HCT-116 human colorectal epithelial cells to test Exclusion (probiotic pre-treatment), Displacement (probiotic post-infection), and Competition (simultaneous inoculation).
  • Immunomodulation: Measured Nitric Oxide (NO) production in RAW 264.7 macrophages infected with EAEC and treated with L. johnsonii.
  • Metabolic Interference: Assessed gas production (fermentation) in a soft agar overlay system.
  • Nutrient Competition: Co-cultured strains in nutrient-rich vs. nutrient-limited media to rule out resource competition.
• Secretome Fractionation:
  • Cell-Free Supernatant (CFS): Prepared and tested for bactericidal activity.
  • FPLC: CFS was fractionated using Fast Protein Liquid Chromatography (Superdex 75 column) to isolate bioactive components <75 kDa.
  • Validation: Active fractions were tested for sustained bactericidal activity (1h vs. 6h) and visualized via Gram staining.

3. Key Contributions

• First Secretome Characterization: This is the first study to fractionate the secretome of L. johnsonii specifically against MDR EAEC, identifying stable, low-molecular-weight bactericidal fractions.
• Mechanistic Differentiation: The study distinguishes between contact-dependent exclusion and secretome-mediated killing, proving that nutrient competition is not the primary mechanism of inhibition for this specific pathotype.
• Dual-Action Validation: Demonstrates that L. johnsonii acts not only as an antimicrobial agent but also as an immunobiotic, significantly reducing host inflammatory responses (NO levels).
• Biofilm Disruption: Provides evidence that active metabolic secretion (not just cell surface components) is required to disrupt EAEC biofilms.

4. Key Results

A. Probiotic Suitability

• Resilience: L. johnsonii showed robust tolerance to pH 1.2–2.0, bile salts, and phenol.
• Adhesion: High cell surface hydrophobicity (74.7–84.4%) and rapid autoaggregation (80.4% by 4 hours), indicating strong potential for mucosal colonization.

B. Antimicrobial Activity

• Potency: L. johnsonii produced a zone of inhibition (3.37 cm) against MDR EAEC that was substantially larger than that of gentamicin (0.37 cm), despite the EAEC strain being resistant to gentamicin.
• Biofilm Disruption: Live L. johnsonii reduced viable biofilm-associated EAEC by 81.4%. Heat-killed bacteria showed no effect, confirming the activity is dependent on active metabolic secretion.
• Gas Production: Co-culture significantly suppressed EAEC-induced gas production, suggesting interference with fermentative metabolism.

C. Competitive Exclusion & Displacement

• Adherence Advantage: L. johnsonii adhered to epithelial cells at nearly double the rate of EAEC (3.35% vs. 1.9%).
• Time-Dependent Efficacy:
  • Exclusion (Pre-treatment): Reduced EAEC colonization by 59.6%.
  • Displacement (Post-treatment): Displaced pre-adhered EAEC by 34.7%.
  • Competition (Simultaneous): No significant reduction, indicating the probiotic requires prior establishment to be effective.
• Nutrient Competition: Ruled out as a mechanism; no significant growth inhibition occurred in nutrient-limited PBS, suggesting the inhibition is secretome-driven.

D. Immunomodulation

• NO Reduction: In EAEC-infected macrophages, L. johnsonii treatment reduced Nitric Oxide levels by 67.7%, indicating a potent anti-inflammatory effect that could mitigate mucosal damage.

E. Bioactive Fraction Identification (FPLC)

• Fractionation: CFS was separated into five fractions (S1, S2, S4, S5, S6) <75 kDa.
• Sustained Activity: While all fractions showed initial activity at 1 hour, only S5 and S6 retained significant bactericidal activity at 6 hours.
• Potency: Fraction S6 was the most potent, reducing EAEC counts by 67.7% (CFU) and 82.1% (Gram stain cell count) after 6 hours. Fraction S5 reduced counts by 58.1% (CFU) and 59.8% (Gram stain).
• Nature of Effectors: The sustained activity of S5/S6 suggests the presence of stable, non-proteinaceous small-molecule effectors (likely fatty acyl derivatives, hydroxy acids, or alkaloids) rather than pH-labile organic acids alone.

5. Significance and Conclusion

This study establishes Lactobacillus johnsonii as a promising biotherapeutic candidate for treating MDR EAEC infections. The findings highlight a multi-faceted mechanism of action:

1. Direct Killing: Via stable, secreted bioactive molecules (fractions S5/S6).
2. Biofilm Disruption: Requiring active metabolism.
3. Colonization Resistance: Through competitive exclusion and displacement of pathogens.
4. Immunomodulation: Dampening the host's inflammatory response.

The identification of specific, stable, low-molecular-weight fractions (S5 and S6) provides a critical foundation for the future development of probiotic-derived antimicrobials or "next-generation probiotics" that do not rely on live bacterial administration, potentially overcoming the challenges of antibiotic resistance and biofilm persistence in pediatric diarrheal diseases. Future work is required to chemically characterize these fractions and validate efficacy in vivo.